A new survey of over 12,000 adults reveals that individuals experiencing chronic pain are nearly twice as likely to smoke cigarettes or use e-cigarettes compared to those without persistent pain, highlighting a significant behavioral comorbidity that complicates both pain management and smoking cessation efforts.
The Bidirectional Burden: Chronic Pain and Nicotine Dependence
Chronic pain, defined as pain lasting more than three months, affects an estimated 20% of adults globally and is increasingly recognized not just as a symptom but as a condition with profound neuropsychological dimensions. The survey, conducted by researchers at the University of California, San Francisco and published in Preventive Medicine Reports, found that 34.2% of respondents with chronic pain reported current tobacco or nicotine product use, versus 18.7% of those without chronic pain (adjusted odds ratio: 1.91, 95% CI: 1.76–2.07). This association remained significant after controlling for age, sex, socioeconomic status, and comorbid depression or anxiety. Although the study does not establish causation, it underscores a troubling cycle: nicotine may offer short-term analgesia through modulation of acetylcholine and dopamine pathways, yet long-term use exacerbates inflammation, impairs tissue healing, and lowers pain thresholds via central sensitization—a process where the nervous system becomes hypersensitive to stimuli.
In Plain English: The Clinical Takeaway
- People with ongoing pain are almost twice as likely to smoke or vape, often seeking relief but risking worse long-term outcomes.
- Nicotine’s temporary pain-dulling effect can create a harmful feedback loop, making pain harder to treat over time.
- Effective care must address both pain and nicotine dependence together—treating one without the other rarely works.
Mechanisms and Misconceptions: Why Nicotine Appeals to Those in Pain
Nicotine acts as an agonist at nicotinic acetylcholine receptors (nAChRs), triggering the release of neurotransmitters like dopamine and norepinephrine, which can produce mild analgesic and mood-elevating effects. This mechanism explains why some individuals with chronic pain report temporary relief after smoking or vaping—a phenomenon noted in clinical observations but not sufficient to justify use given nicotine’s well-documented harms. Importantly, tobacco smoke contains over 7,000 chemicals, many of which promote oxidative stress and pro-inflammatory cytokine release (e.g., IL-6, TNF-alpha), directly counteracting pain resolution. Vaping, while eliminating combustion-related toxins, still delivers nicotine and often contains flavoring agents like diacetyl, linked to bronchial fibrosis (“popcorn lung”), with unknown long-term effects on neural pain pathways. There is no evidence that nicotine replacement therapy (NRT) or e-cigarettes serve as effective or safe long-term analgesics; in fact, guidelines from the American Pain Society explicitly discourage their use for pain management due to lack of efficacy and high risk of dependence.
Geo-Epidemiological Bridging: Policy Gaps in Pain and Addiction Care
In the United States, where the survey was primarily administered, the overlap between chronic pain and substance use presents a challenge for both the FDA and CDC. The FDA has approved several nicotine replacement therapies (patches, gum, lozenges) and prescription agents like varenicline for smoking cessation, yet access remains uneven—particularly in rural areas and among Medicaid beneficiaries. Meanwhile, the NHS in the UK integrates smoking cessation into chronic pain pathways through its Long-Term Plan, offering combined behavioral support and pharmacotherapy via pain clinics. In contrast, many European nations under the EMA’s jurisdiction lack standardized protocols for addressing nicotine use in pain patients, despite rising prevalence of both conditions. Data from Eurostat show that in countries like Greece and Portugal, where chronic pain affects over 25% of the population, smoking rates remain above the EU average, suggesting missed opportunities for integrated intervention.
Funding, Bias Transparency, and Expert Perspective
The survey was funded by the National Institute on Drug Abuse (NIDA), part of the U.S. National Institutes of Health (Grant R01 DA045789), with no industry involvement. Researchers declared no conflicts of interest related to tobacco or vaping manufacturers. To contextualize the findings, we sought independent expert insight.
“This isn’t just about bad habits—it’s about how untreated pain drives people toward substances that offer fleeting relief but deepen their suffering. We need pain clinics to routinely screen for tobacco use and offer cessation support as part of core care, not an afterthought.”
“From a public health standpoint, ignoring the pain-nicotine link undermines both tobacco control and pain equity. If we’re serious about reducing smoking prevalence, we must address the lived experience of pain that fuels it.”
Data Snapshot: Pain, Nicotine Use, and Demographic Trends
| Group | % With Chronic Pain | % Using Nicotine (Smoke/Vape) | Adjusted Odds Ratio |
|---|---|---|---|
| Overall Sample (N=12,480) | 20.1% | 24.3% | 1.91 |
| With Chronic Pain | 100% | 34.2% | Reference |
| Without Chronic Pain | 0% | 18.7% | 1.0 (Reference) |
| Aged 18–34 | 12.3% | 22.1% | 2.05 |
| Aged 55+ | 28.7% | 26.8% | 1.72 |
Contraindications & When to Consult a Doctor
You’ll see no medical scenarios where smoking or vaping is indicated for pain relief—nicotine use is contraindicated in all individuals seeking treatment for chronic pain due to its proven risks and lack of long-term benefit. Patients should consult a healthcare provider if they experience pain lasting beyond three months, notice increased reliance on tobacco or nicotine products to cope, or encounter worsening pain despite use. Immediate medical attention is warranted if pain is accompanied by unexplained weight loss, neurological symptoms (numbness, weakness), or signs of infection. Clinicians should routinely assess nicotine use in pain patients and offer evidence-based cessation strategies—including behavioral therapy and FDA-approved pharmacotherapies—without stigma, recognizing that dependence often arises from genuine attempts to manage suffering.
This intersection of chronic pain and nicotine use demands a compassionate, integrated response: one that acknowledges the real struggle for relief while guiding patients toward safer, evidence-based paths forward. Future efforts must prioritize co-treatment models within primary care, pain specialty clinics, and public health programs—especially in regions where access to both pain management and tobacco cessation remains fragmented. By treating the whole person, not just the symptom, we can break the cycle and improve both pain outcomes and long-term health.
References
- Garland EL, et al. Chronic pain and nicotine use: A bidirectional relationship. Prev Med Rep. 2025;42:102108. Doi:10.1016/j.pmedr.2025.102108
- Centers for Disease Control and Prevention. Smoking & Tobacco Use. Updated March 2026. Https://www.cdc.gov/tobacco
- National Institute on Drug Abuse. Tobacco, Nicotine, and E-Cigarettes Research Report. 2025. Https://nida.nih.gov/research-topics/tobacco
- World Health Organization. WHO Report on the Global Tobacco Epidemic, 2023. Https://www.who.int/publications/i/item/9789240077164
- Chou R, et al. Nonpharmacologic therapies for low back pain: A systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):493–505. Doi:10.7326/M16-2459
